US drug pricing reform happens at last
As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.
Private equity gets serious about drug development
Venture capital has the brains, private equity has the books – can they make lots of money?
Are we there yet?
Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.
The Cytomx paradox
Failure of the company’s in-house lead raises questions about the viability of its extensively partnered probody technology.
